{
  "id": 16921034,
  "title": "Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial",
  "url": "https://urgent.news/2026/10/28/lillys-triple-g-drug-tops-novos-ozempic-in-diabetes-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T15:53:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/retatrutide-ozempic-diabetes-trial-results-lilly-novo/873016/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Lilly's ads can continue after Novo challenge, judge rules",
        "url": "https://urgent.news/2026/10/27/lillys-ads-can-continue-after-novo-challenge-judge-rules",
        "published": "2026-10-27T18:23:59.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}